Hallym Sitagliptin Tablets 100mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Hallym Pharmaceutical Co., Ltd.
MFDS item code 201503151 · Approved 2015.05.26
This product's status changed to Approval withdrawn on 2024.03.06. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with type 2 diabetes. It can be administered alone as an adjunct to dietary therapy and exercise therapy, and in patients without prior experience of diabetes medication, it is co-administered with metformin if blood sugar control is difficult. Furthermore, in cases where blood sugar control is inadequate with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin, this medication is used in combination. It helps effectively manage blood sugar by adding this medication when blood sugar control is insufficient with various combination therapies. This medication plays a significant role in enhancing blood sugar control.
This drug is administered at 100 mg once daily when used as monotherapy or in combination therapy, and the maximum daily dose is 100 mg. This drug may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2), administer 50 mg once daily. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This drug may be administered without regard to the timing of dialysis.
This medication may cause allergic reactions. If signs such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a doctor. While taking this medication, inflammation of the pancreas (pancreatitis) may occur, so if you experience severe abdominal pain or vomiting, notify your healthcare provider immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Patients with decreased kidney function need to have their dosage adjusted, and it is important to undergo kidney function tests periodically. During treatment, symptoms such as headaches, upper respiratory infections, nasopharyngitis, diarrhea, etc., may appear; if symptoms are severe, consult your doctor. The risk of hypoglycemia may increase when used with insulin or sulfonylureas, so blood sugar levels should be closely monitored. If symptoms of severe joint pain or skin blisters occur, discontinue the medication and inform your doctor immediately. Pregnant women should avoid this medication as its safety has not been established. Breastfeeding women are also recommended not to take this medication as it may be excreted in breast milk. In children and adolescents, the safety and efficacy of this medication have not been established, so it is not used. Elderly patients may have reduced kidney function requiring dosage adjustments and kidney function testing. In cases of overdose, seek appropriate treatment immediately at a medical institution. This medication may be partially removed by hemodialysis. This medication may interact with other drugs, so it is essential to inform the doctor or pharmacist of any medications currently being taken. Clinical trial results on cardiovascular safety have confirmed that this medication does not increase the risk of cardiovascular diseases.
Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative skin conditions, acute pancreatitis, hypoglycemia, upper respiratory tract infections, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, dyspepsia, dizziness, elevated liver enzymes, acute renal failure, constipation, vomiting, severe joint pain accompanied by disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, elevated blood triglycerides, increased low-density lipoprotein, hyperglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air exposure, at a temperature between 1°C and 30°C. This is to maintain the medication's effectiveness and prevent deterioration.
Beige, round, film-coated tablets with both sides convex
28 tablets (14 tablets per PTP packaging × 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Hallym Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.